A Phase 3 interventional study of HS-25 and Atorvastatin and Atorvastatin in Hypercholesterolemia in Coronaory Heart Disease, sponsored by Zhejiang Hisun Pharmaceutical Co. Ltd.. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-10-18.
Sponsored by Zhejiang Hisun Pharmaceutical Co. Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies testing atorvastatin in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Hypercholesterolemia.
Among the 77 studies testing atorvastatin in Hypercholesterolemia, this one is the 32nd largest by enrollment of the 75 interventional ones that give a count, is the only one that started in 2016, is one of 31 in phase 3, and was the 69th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 77 studies testing atorvastatin in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:
Punjab Institute of Cardology · Sites in Pakistan
Ages 18+
By country, each count listing its studies:
Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →
Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 255 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 148 across the 75 interventional studies. Of the 69 that completed or were terminated, 33 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 77 have an industry lead sponsor. The 10 most frequent:
Zhejiang Hisun Pharmaceutical Co. Ltd. is the lead sponsor of 18 studies on the registry; 2 are open to participants now.
Zhejiang Hisun Pharmaceutical Co. Ltd. has 4 studies filed under Hypercholesterolemia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 77 studies testing atorvastatin in Hypercholesterolemia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To determine the efficacy of HS-25 (20mg) in reducing low density lipoprotein-cholesterol (LDL-C) levels after a 12-week period of treatment in combination with Atorvastatin in subjects with hypercholesterolemia and coronary heart diseases; To determine the safety of HS-25 (20mg) combination with Atorvastatin in subjects with hypercholesterolemia and coronary heart diseases
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must meet the one of diseases as following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HS-25 20mg, Atorvastatin 10mg, Placebo of Atorvastatin 1 tablet
Drug: HS-25 and Atorvastatin
Atorvastatin 20mg, Placebo of HS-25 2 tablets
Drug: Atorvastatin
Drug pages: HS-25 · Atorvastatin
HS-25 20mg (2 tablets), Atorvastatin 10mg, Placebo of Atorvastatin 1 tablet oral, once daily
Atorvastatin 20mg (2 tablets), Placebo of HS-25 2 tablets, oral, once daily
Percent change of LDL-C
Percent change from baseline in LDL-C after 2,4,8,12 weeks of double-blind treatment
Time frame: 2,4,8,12 weeks
Percent change of Non-HDL-C
Percent change from baseline in Non-HDL-C after 2,4,8,12 weeks of double-blind treatment
Time frame: 2,4,8,12 weeks
Percent change of TC,TG,ApoB,ApoAI
Percent change from baseline in TC,TG,ApoB and ApoAI after 2,4,8,12 weeks of double-blind treat
Time frame: 2,4,8,12 weeks
No study locations are listed for this record.
Ran from Jun 2016 to primary completion in Jun 2018, 24 months.
Of 123 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 24 months is above that.
Counting every sponsor, half of 126 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: HS-25 · Atorvastatin
Zhejiang Hisun Pharmaceutical Co. Ltd.